Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
ACT [NYSE]
Actavis plc
IndexS&P 500 P/E- EPS (ttm)-4.08 Insider Own0.40% Shs Outstand265.08M Perf Week-2.02%
Market Cap56.80B Forward P/E12.88 EPS next Y16.63 Insider Trans33.66% Shs Float263.87M Perf Month-4.35%
Income-551.10M PEG- EPS next Q3.36 Inst Own61.90% Short Float1.12% Perf Quarter3.12%
Sales9.44B P/S6.02 EPS this Y-793.40% Inst Trans0.89% Short Ratio1.41 Perf Half Y14.77%
Book/sh55.38 P/B3.87 EPS next Y21.89% ROA-3.00% Target Price261.85 Perf Year59.57%
Cash/sh1.28 P/C166.95 EPS next 5Y19.87% ROE-8.30% 52W Range130.06 - 230.77 Perf YTD27.54%
Dividend- P/FCF52.66 EPS past 5Y-35.20% ROI-3.00% 52W High-7.15% Beta0.33
Dividend %- Quick Ratio0.90 Sales past 5Y27.90% Gross Margin48.10% 52W Low64.74% ATR3.76
Employees19200 Current Ratio1.50 Sales Q/Q40.10% Oper. Margin16.90% RSI (14)43.13 Volatility1.43% 1.66%
OptionableYes Debt/Eq0.91 EPS Q/Q169.60% Profit Margin-5.80% Rel Volume1.44 Prev Close215.55
ShortableYes LT Debt/Eq0.88 EarningsAug 05 BMO Payout- Avg Volume2.11M Price214.26
Recom1.60 SMA20-1.61% SMA50-0.65% SMA20011.52% Volume3,032,692 Change-0.60%
02-Jul-14Reiterated CRT Capital Buy $245 → $275
27-Jun-14Initiated Canaccord Genuity Buy $275
12-May-14Upgrade RBC Capital Mkts Outperform → Top Pick $252 → $259
01-May-14Reiterated CRT Capital Buy $230 → $245
28-Apr-14Reiterated National Alliance Securities Buy $246 → $259
17-Apr-14Initiated National Alliance Securities Buy $246
21-Feb-14Reiterated RBC Capital Mkts Outperform $240 → $249
19-Feb-14Reiterated UBS Buy $202 → $237
19-Feb-14Reiterated CRT Capital Buy $210 → $230
19-Feb-14Reiterated Barclays Overweight $230 → $250
03-Feb-14Reiterated RBC Capital Mkts Outperform $202 → $222
03-Feb-14Reiterated Barclays Overweight $190 → $230
17-Jan-14Reiterated Argus Buy $180 → $198
07-Jan-14Initiated RBC Capital Mkts Outperform $202
30-Oct-13Reiterated Barclays Overweight $175 → $190
16-Sep-13Reiterated Barclays Overweight $140 → $175
30-Jul-13Reiterated Argus Buy $120 → $150
26-Jul-13Reiterated CRT Capital Buy $140 → $150
30-May-13Reiterated UBS Buy $120 → $155
30-May-13Reiterated RBC Capital Mkts Outperform $108 → $136
31-Jul-14 02:51PM  Many Leading Stocks Damaged As Market Tumbles Broadly at Investor's Business Daily
10:48AM  3 Eye-Catching Health Care Stocks this Earnings Season Zacks
30-Jul-14 07:11AM  AstraZeneca buys Almirall lung drugs for up to $2.1 billion Reuters
29-Jul-14 12:46PM  Merck Pops On Good Profits, Tax Deal? at Barrons.com
28-Jul-14 06:03PM  Actavis May Give Buyers Another Chance at Investor's Business Daily
25-Jul-14 04:33PM  Activis Shares Languish Post-Forest Deal Benzinga
24-Jul-14 09:30AM  The Best Health Care Stock To Own Right Now StreetAuthority Network
09:30AM  Is This The Best Health Care Stock To Own Right Now? StreetAuthority Network
08:56AM  Is Teva Pharmaceuticals Stock Really Your Best Generic Drug Investment Option? at Motley Fool
21-Jul-14 04:30PM  Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert IUD PR Newswire
18-Jul-14 05:15PM  Synergy Pharmaceuticals Progresses with Mid-Stage Candidate Zacks
17-Jul-14 01:04PM  ACTAVIS PLC Financials EDGAR Online Financials
16-Jul-14 02:19PM  Actavis Looks To Keep Up Momentum In Spite Of Yellen's Report Benzinga
12:03PM  Mylan (MYL) Joins the Tax-Inversion Wave Zacks
11:19AM  Leon Cooperman talks up Citi, Thermo Fisher at MarketWatch
11:09AM  [video] Cooperman's best ideas for 2014 at CNBC
10:59AM  [video] Cooperman: Buy Citi, Atlas and these other stocks now at CNBC
14-Jul-14 05:30PM  Actavis Fuels Growth With Acquisitions, New Generics at Investor's Business Daily
02:54PM  Mylan in $5.3bn Abbott Laboratories deal at Financial Times
11-Jul-14 04:31PM  Actavis confirms generic Diclegis patent challenge theflyonthewall.com
04:25PM  Actavis Confirms Generic Diclegis® Patent Challenge PR Newswire
10-Jul-14 08:43AM  [video] Acorda 'firmly on the side of research': CEO at CNBC
09-Jul-14 04:10PM  Synergy Pharmaceuticals' Plecanatide to Move into Phase III Zacks
08-Jul-14 04:05PM  Actavis Confirms Generic Ampyra® Patent Challenge PR Newswire
01:28PM  Stocks Ease Off Lows; King Digital Turns Tail at Investor's Business Daily
03-Jul-14 05:03PM  ACTAVIS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition EDGAR Online
02-Jul-14 04:05PM  Impax Acquires Two Products from Actavis PR Newswire
01:04PM  ACTAVIS PLC Financials EDGAR Online Financials
08:49AM  Actavis completes acquisition of Furiex theflyonthewall.com
08:46AM  Actavis Completes Acquisition of Furiex Pharmaceuticals PR Newswire
08:00AM  Actavis Announces Final Stockholder Merger Consideration Election Results in Connection with Forest Laboratories Acquisition PR Newswire
12:01AM  Hobby Lobby Discounts Outweigh Dismay Over Court Ruling at Bloomberg
01-Jul-14 12:10PM  Actaviss Dealmaking New CEO Has Zero Plans for Sale at Bloomberg
11:16AM  Actavis represents good takeover alternative for Pfizer, says Leerink theflyonthewall.com
10:23AM  Actavis closes $28B Forest deal, names new CEO AP
09:00AM  Actavis plc Appoints New Members and Announces Changes to Board of Directors Following Close of Forest Laboratories, Inc. Acquisition PR Newswire
08:42AM  Why Actavis (ACT) Stock May Move Higher Today at TheStreet
08:31AM  [video] Actavis completes deal to buy Forest Labs at CNBC
08:30AM  Actavis Completes Forest Laboratories Acquisition PR Newswire
08:20AM  Actavis Completes Forest Laboratories Acquisition PR Newswire
12:10AM  The Supreme Court's Hobby Lobby Decision Didn't Overturn A Single Word Of Obamacare at Forbes
12:10AM  According to the Supreme Court, Corporations Have More Religious Freedom Than Taxpayers at Forbes
30-Jun-14 05:34PM  [$$] Actavis, Forest To Sell or Relinquish Generics Rights at The Wall Street Journal
05:15PM  Actavis and Forest Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Forest PR Newswire
05:15PM  Actavis and Forest Receive U.S. FTC Clearance for Actavis Proposed Acquisition of Forest Business Wire
05:12PM  U.S. allows Actavis Plc's purchase of Forest Labs with conditions Reuters
09:29AM  [$$] Actavis Says Holders of 73% of Forest Shares Elect Stock at The Wall Street Journal
08:36AM  Actavis, Forest Labs announce merger consideration election results at theflyonthewall.com
08:30AM  Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results PR Newswire
08:30AM  Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results Business Wire
08:00AM  Actavis to Host Second Quarter 2014 Earnings Conference Call and Webcast PR Newswire
07:30AM  Actavis confirms generic Zubsolv patent challenge theflyonthewall.com
07:30AM  Actavis Confirms Generic Zubsolv® Patent Challenge PR Newswire
27-Jun-14 07:08PM  Many IBD 50 Stocks Struggle To Climb After Breakouts at Investor's Business Daily
07:08PM  Many IBD 50 Stocks Struggle To Climb After Breakouts
08:20AM  Top Analyst Upgrades and Downgrades: Alcoa, Cigna, Intel, Molina, Teva, UnitedHealth and More
07:54AM  Coverage initiated on Actavis by Canaccord Genuity Briefing.com
07:54AM  Coverage initiated on Actavis by Canaccord Genuity
26-Jun-14 06:41PM  Novo, Other Medicals Display Healthy Action at Investor's Business Daily
06:41PM  Novo, Other Medicals Display Healthy Action
06:36AM  Acorda's multiple sclerosis drug faces generic threat Reuters
06:36AM  Acorda's multiple sclerosis drug faces generic threat
06:03AM  Acorda Therapeutics notified of Actavis' ANDA filing for generic Ampyra at theflyonthewall.com
06:03AM  Acorda Therapeutics notified of Actavis' ANDA filing for generic Ampyra
25-Jun-14 05:30PM  Are Investors Wrong About VIVUS?
02:20PM  Endo International to Expand Generics Business with DAVA Buy
10:34AM  Love the Stocks Everyone Hates: 5 Short-Squeeze Stocks Ready to Pop
02:19AM  U.S. court backs Shire in patent fight over Vyvanse drug Reuters
02:19AM  U.S. court backs Shire in patent fight over Vyvanse drug
24-Jun-14 06:50PM  Affiliated Managers Group Set to Join S&P 500; LaSalle Hotel Properties, Rayonier Advanced Materials, TimkenSteel, Belden to Join the S&P MidCap 400; Others to Join S&P SmallCap 600 PR Newswire
06:50PM  Affiliated Managers Group Set to Join S&P 500; LaSalle Hotel Properties, Rayonier Advanced Materials, TimkenSteel, Belden to Join the S&P MidCap 400; Others to Join S&P SmallCap 600
04:48PM  ACTAVIS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  Actavis and Forest Announce Tentative Election Deadline Of June 27, 2014 PR Newswire
08:30AM  Actavis and Forest Announce Tentative Election Deadline of June 27, 2014 Business Wire
08:30AM  Actavis and Forest Announce Tentative Election Deadline Of June 27, 2014
08:30AM  Actavis and Forest Announce Tentative Election Deadline of June 27, 2014
23-Jun-14 01:29PM  Major Indexes Narrowly Lower As Actavis Rallies at Investor's Business Daily
01:29PM  Major Indexes Narrowly Lower As Actavis Rallies
12:59PM  Can Cancer Patients Really Get 'Drunk' From Docetaxel?
11:41AM  Unusual Social Activity Today Around Actavis (ACT)
08:30AM  Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
20-Jun-14 05:11PM  ACTAVIS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation EDGAR Online
05:11PM  ACTAVIS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
19-Jun-14 08:30AM  Actavis Confirms District Court Ruling In Generic Exelon® Patch Patent Suit PR Newswire
08:30AM  Actavis Confirms District Court Ruling In Generic Exelon® Patch Patent Suit
18-Jun-14 04:20PM  Nasdaq, S&P 500 Rally To New Highs After Fed Meeting at Investor's Business Daily
04:20PM  Nasdaq, S&P 500 Rally To New Highs After Fed Meeting
08:02AM  Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry at Investor's Business Daily
08:02AM  Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry
17-Jun-14 05:18PM  ACTAVIS PLC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statemen EDGAR Online
05:18PM  ACTAVIS PLC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statemen
04:43PM  After-hours buzz: Adobe Systems, La-Z Boy & more at CNBC
04:43PM  After-hours buzz: Adobe Systems, La-Z Boy & more
04:05PM  Actavis and Forest Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Forest PR Newswire
04:05PM  Actavis and Forest Shareholders Approve Proposals Related to Actavis Planned Acquisition of Forest Business Wire
04:05PM  Actavis and Forest Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Forest
04:05PM  Actavis and Forest Shareholders Approve Proposals Related to Actavis Planned Acquisition of Forest
08:05AM  Teva reaches settlement in NUVIGIL patent case theflyonthewall.com
08:05AM  Teva reaches settlement in NUVIGIL patent case
13-Jun-14 04:33PM  ACTAVIS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians' offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.